Back to News
Market Impact: 0.3
Rhythm Launches Imcivree In Japan For Acquired Hypothalamic Obesity
Source: Nasdaq
Healthcare & BiotechProduct Launches
Rhythm Pharmaceuticals launched Imcivree (setmelanotide) commercially in Japan for acquired hypothalamic obesity after the drug was added to Japan’s National Health Insurance drug price list. The article provides no sales, pricing, or financial impact figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
RYTM0.65
More News
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
- Razer’s CEO waited 20 years for everyone to become a gamer. He says AI is finally making it happen
- Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD
- Tech giants race to get AI gadgets on shelves for holiday rush
- Electric vehicle sales in the U.S. are showing signs of life
- Delta knows the top 40% of Americans are $40 trillion richer than just a few years ago. Cue new burgers and bourbon on Delta One’s biggest revamp yet